| Dr John Gurski, DO, | |
|
420 S 5th Ave, West Reading, PA 19611-2143 | |
| (484) 628-9049 | |
| Not Available |
| Full Name | Dr John Gurski |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 9 Years |
| Location | 420 S 5th Ave, West Reading, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114309390 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | OS019886 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Reading Hospital | West reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tower Health Medical Group | 7618889213 | 577 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
Diversified Service Options, Inc., (Diversified) today announced that the company and its wholly-owned subsidiaries, First Coast Service Options and Novitas Solutions, have achieved the prestigious Health Ethics Trust's Compliance Program certification for their compliance program, Navigator.
Researchers in San Diego have conducted a study showing that both smoking and the use of e-cigarettes containing nicotine and flavorings may critically exacerbate inflammation in cases of coronavirus disease 2019 (COVID-19) and significantly worsen clinical outcomes.
The Nuclear Magnetic Resonance facility at the Florida campus of The Scripps Research Institute is becoming one of the most advanced in South Florida, thanks to a new $600,000 grant from the National Institutes of Health.
SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.
› Verified 3 days ago
| Entity Name | Tower Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609291350 PECOS PAC ID: 7618889213 Enrollment ID: O20040311000072 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
Diversified Service Options, Inc., (Diversified) today announced that the company and its wholly-owned subsidiaries, First Coast Service Options and Novitas Solutions, have achieved the prestigious Health Ethics Trust's Compliance Program certification for their compliance program, Navigator.
Researchers in San Diego have conducted a study showing that both smoking and the use of e-cigarettes containing nicotine and flavorings may critically exacerbate inflammation in cases of coronavirus disease 2019 (COVID-19) and significantly worsen clinical outcomes.
The Nuclear Magnetic Resonance facility at the Florida campus of The Scripps Research Institute is becoming one of the most advanced in South Florida, thanks to a new $600,000 grant from the National Institutes of Health.
SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.
› Verified 3 days ago
| Entity Name | Reading Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992387518 PECOS PAC ID: 7618886490 Enrollment ID: O20040408001076 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
Diversified Service Options, Inc., (Diversified) today announced that the company and its wholly-owned subsidiaries, First Coast Service Options and Novitas Solutions, have achieved the prestigious Health Ethics Trust's Compliance Program certification for their compliance program, Navigator.
Researchers in San Diego have conducted a study showing that both smoking and the use of e-cigarettes containing nicotine and flavorings may critically exacerbate inflammation in cases of coronavirus disease 2019 (COVID-19) and significantly worsen clinical outcomes.
The Nuclear Magnetic Resonance facility at the Florida campus of The Scripps Research Institute is becoming one of the most advanced in South Florida, thanks to a new $600,000 grant from the National Institutes of Health.
SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.
› Verified 3 days ago
| Entity Name | Reading Behavioral Healthcare, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750997466 PECOS PAC ID: 8527495183 Enrollment ID: O20201209001899 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
Diversified Service Options, Inc., (Diversified) today announced that the company and its wholly-owned subsidiaries, First Coast Service Options and Novitas Solutions, have achieved the prestigious Health Ethics Trust's Compliance Program certification for their compliance program, Navigator.
Researchers in San Diego have conducted a study showing that both smoking and the use of e-cigarettes containing nicotine and flavorings may critically exacerbate inflammation in cases of coronavirus disease 2019 (COVID-19) and significantly worsen clinical outcomes.
The Nuclear Magnetic Resonance facility at the Florida campus of The Scripps Research Institute is becoming one of the most advanced in South Florida, thanks to a new $600,000 grant from the National Institutes of Health.
SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Gurski, DO, 5501 Old York Rd, Philadelphia, PA 19141-3018 Ph: (215) 456-9015 | Dr John Gurski, DO, 420 S 5th Ave, West Reading, PA 19611-2143 Ph: (484) 628-9049 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
Diversified Service Options, Inc., (Diversified) today announced that the company and its wholly-owned subsidiaries, First Coast Service Options and Novitas Solutions, have achieved the prestigious Health Ethics Trust's Compliance Program certification for their compliance program, Navigator.
Researchers in San Diego have conducted a study showing that both smoking and the use of e-cigarettes containing nicotine and flavorings may critically exacerbate inflammation in cases of coronavirus disease 2019 (COVID-19) and significantly worsen clinical outcomes.
The Nuclear Magnetic Resonance facility at the Florida campus of The Scripps Research Institute is becoming one of the most advanced in South Florida, thanks to a new $600,000 grant from the National Institutes of Health.
SANUWAVE Health, Inc., today announced the publication of peer-reviewed, preclinical research that demonstrates the ability of the Company's Extracorporeal Shock Wave Technology (ESWT) to stimulate proliferation of periosteal adult stem cells (cambium cells) within the body and subsequently form bone.
› Verified 3 days ago
Dr. Mohammad Ali Khoshnoodi, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 301 S 7th Ave Ste 210, West Reading, PA 19611 Phone: 484-628-4656 | |
Dr. Jayesh P Patel, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-4879 | |
Jaswin Singh, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 | |
Kolin Diane Good, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6th & Spruce Streets, Reading Hospital, West Reading, PA 19611 Phone: 484-628-8070 Fax: 484-628-5289 | |
Dr. Lawrence A Brzozowski, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 301 S 7th Ave, 210, West Reading, PA 19611 Phone: 484-628-4656 Fax: 484-628-4657 | |
Wajihah Memon, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 |